KLOW peptide is a four-peptide research blend whose four stars no controlled study has ever joined.

Start here

KLOW peptide is a research-only mixture of four small protein fragments — KPV, GHK-Cu, BPC-157 and TB-500 — dissolved together in one vial. It is not a single drug. Think of it less as one star and more as four stars in the same patch of sky: each peptide has its own separate body of research, and each touches a different part of how the body repairs tissue. KPV is the anti-inflammatory one. GHK-Cu (a copper-carrying peptide) is the one tied to collagen and skin. BPC-157 is the one studied for tendons and new blood vessels. TB-500 is the one linked to cells migrating to close a wound. The honest headline is this: no controlled study has ever tested the four together. Every claim that they work as a blend is an educated guess drawn from four separate literatures — and none of the four is FDA-approved. What people report — including the downsides — is laid out on reported effects and safety.

What is KLOW peptide?

What is KLOW peptide?

KLOW peptide is a co-formulation: four chemically distinct research peptides co-dissolved in a single vial at fixed mass ratios. They do not bond into one new molecule — they remain four separate compounds sharing a solution. The most widely listed research-vial composition across independent compounders is an 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. There is no FDA-approved or pharmacopeial KLOW product; it is supplied strictly as a research-chemical co-formulation.

The four peptides were chosen because their individual mechanisms sit at largely separate nodes of one tissue-repair network. KPV (the C-terminal tripeptide of alpha-MSH, a hormone fragment) suppresses inflammatory signaling ^[3]. GHK-Cu (Copper Tripeptide-1) shifts a large fraction of assayed genes toward matrix synthesis and repair in cultured cells ^[5]. BPC-157 (a 15-amino-acid peptide derived from a gastric-juice protein) drives new blood-vessel growth through the VEGFR2 receptor ^[6]. TB-500 (a synthetic fragment of thymosin beta-4) is linked to cell migration through actin binding ^[1]. Four arms, one cascade — at least in theory.

KLOW blend composition

What is in the 80mg KLOW peptide vial?

The canonical 80 mg research vial holds GHK-Cu 50 mg — roughly 62.5% of the mass, the brightest star of the four — alongside BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. GHK-Cu being mass-dominant matters: it carries a chelated copper(II) ion, which is also why a reconstituted KLOW solution often reads blue ^[4]. The four are co-dissolved at fixed ratios and remain four separate molecules, not a single chemical complex.

Because it is a mixture, KLOW has no single molecular weight, no CAS number, and no PubChem identifier — those exist only per component. That distinction is the spine of this whole site: a blend is read most honestly as the sum of four well-attributed parts, with each finding kept on the peptide it actually came from. The full breakdown sits in the four-peptide composition and is carried through every page.

What the four-component literature has shown

The strongest evidence belongs to the individual peptides, in mostly preclinical work. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional and microscopic measures ^[2], and improved transected rat medial collateral ligament healing as well ^[11]. Thymosin beta-4 — the full-length parent protein of the TB-500 fragment — raised re-epithelialization (the regrowth of the skin's surface layer) by 42% at four days and up to 61% at seven days in a rat wound model ^[1]. GHK-Cu stimulates collagen and proteoglycan synthesis, and topical GHK-Cu increased collagen production in 70% of treated women in a comparison review ^[4]. KPV, carried into gut-lining cells by the PepT1 transporter, lowered inflammatory cytokine output and reduced colitis severity in mice ^[3].

These are real, cited, single-component findings. None of them is a finding about KLOW. The whole rationale for combining them — and where it stays honest about the gap — is set out in the KLOW blend rationale.

What does the KLOW peptide do?

What does the KLOW peptide do?

Mechanistically, the four arms address complementary steps of repair: KPV suppresses NF-kB-driven inflammatory transcription ^[3], GHK-Cu drives matrix and collagen synthesis with broad gene-expression shifts ^[5], BPC-157 activates VEGFR2 angiogenesis ^[6], and TB-500 sequesters G-actin for cell migration ^[1]. These are single-component mechanisms; the blend itself is untested.

What is KLOW peptide used for?

In the research literature its four components occupy non-overlapping nodes of one tissue-repair cascade: inflammation (KPV), matrix and collagen (GHK-Cu), angiogenesis and tendon (BPC-157), and wound closure (TB-500). All combination uses are mechanistic extrapolation from single-component studies, not blend trials. The dosing picture — and why the four half-lives do not line up — is on KLOW dosing context.